Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating

Holvoet, Tom; Joossens, Marie; Wang, Jun; Boelens, Jerina; Verhasselt, Bruno; Laukens, Debby; Vlierberghe, Hans Van; Hindryckx, Pieter; Vos, Martine De; Looze, Danny De; Raes, Jeroen

doi:10.1136/gutjnl-2016-312513

Cited by 62 publications

(69 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients treated with FMT showed a significant clinical response at three months compared to those in the placebo group (65% vs. 43%, p = 0.049) [39]. These findings were further confirmed by other recent studies showing a positive effect on IBS symptoms after transplant, as 70-85% and 45-60% of patients reported symptomatic relief in the first three months and six months after FMT, respectively [81,82]. On the contrary, a recent study including 52 IBS adult patients who were randomized to either active FMT or placebo capsules administered for 12 months did not show beneficial effects favoring FMT at three months.…”

Section: Fecal Microbiota Transplantationsupporting

confidence: 79%

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Mari

Baker

Mahamid

et al. 2020

JCM

View full text Add to dashboard Cite

The intestinal microbiota is one of the most rapidly evolving areas in biology and medicine. Extensive research in the last decade has escalated our understanding of the role of the microbiota in the pathogenesis of several intestinal and extra-intestinal disorders. Marked by high prevalence, substantial morbidity, and enormous costs, irritable bowel syndrome (IBS) is an important chronic gastrointestinal disorder that is widely encountered by gastroenterologists. Despite advances in our understanding of its pathophysiology, curative interventions have yet to be discovered, and therapeutic approaches remain symptom-driven. Recently, accumulating evidence has enlightened the possible impact of an imbalanced gut microbiome in the pathogenesis of IBS. In fact, several studies have documented altered microbiota in patients, while others have shown that IBS severity was associated with a distinct microbiota signature. These findings may pave the way for the use of microbiota manipulation strategies as an attractive option for IBS management, and may have an essential role in efforts to reduce the societal and economic effects of this ever-growing disorder. In this review, we have outlined the results of the latest research on the association between microbiota and IBS and their implications for the clinical management of affected patients.

show abstract

Section: Fecal Microbiota Transplantationsupporting

confidence: 79%

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Mari

Baker

Mahamid

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Johnsen et al performed the first RCT on FMT in treating moderate‐to‐severe IBS and showed that the effect of FMT was superior to that of a placebo at 3 months. Another study found that 75% of patients with IBS experienced relief from IBS symptoms and abdominal bloating 12 weeks after FMT. At follow‐up, 78% of the responders stated that they had significant relief from IBS symptoms after 1 year, suggesting a long‐lasting effect of FMT on IBS.…”

Section: Discussionmentioning

confidence: 99%

“…Imbalances in gut microbiota may negatively influence intestinal secretion and motility, even causing IBS. Holvoet et al reported that the positive effects of FMT on IBS‐related symptoms could be linked to changes in the gut microbiota. FMT, as a treatment option for IBS, could modify gut microbiota composition, suggesting that there is a significant correlation between abnormal gut microbiota and IBS.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota

Huang

Chen

Luo

et al. 2019

J of Digest Diseases

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety of fecal microbiota transplantation (FMT) for refractory irritable bowel syndrome (IBS). Methods Microbiota suspensions from feces of the donors were injected into the intestines of 30 Chinese patients with refractory IBS. Microbiota composition analysis and genomic DNA extraction of fecal samples obtained from these patients at baseline and 1 month after FMT were performed. Clinical efficacy and safety of FMT were assessed using questionnaires covering four aspects of IBS therapeutic efficacy and assessment of adverse effects during a 6‐month follow‐up. Results FMT improved IBS gastrointestinal symptoms and alleviated depression and anxiety, as shown by the improved IBS‐QOL, IBS‐SSS, GSRS, HAMA and HAMD scores at 1 month and 3 months after FMT. A total adverse event rate of FMT was 6.7% (2/30). Gut microbiota analysis revealed that FMT responders had a significantly higher Shannon diversity index before FMT than non‐responders. In addition, analysis of differences in bacterial composition before and after FMT in responders showed specific abundance of the phyla Verrucomincrobia and Euryarchaeota at 1 month after FMT. At the genus level, Methanobrevibacter and Akkermansia were the most abundant fecal microbiota 1 month after FMT compared with those before FMT. Conclusions FMT may be an effective and safe therapeutic strategy for treating IBS that achieves a sustained clinical response 3‐6 months after the first procedure. Changes in the diversity and dominant flora may contribute to its therapeutic effect.

show abstract

“…Neben dem in dieser Studie vorgestellten RDS-Behandlungsansatz gibt es noch andere vielversprechende Behandlungsmöglichkeiten. So konnte man durch den Einsatz von Probiotika [3,[10][11][12] und Fäkaltransplantationen [13,14] …”

Section: Introductionunclassified

Homöopathisch-phytotherapeutische Behandlung des Reizdarmsyndroms mit Magen-Darm-Entoxin N®: Eine Anwendungsbeobachtung

Märtens¹,

Range²,

Günnewich³

et al. 2017

Complement Med Res

View full text Add to dashboard Cite

Hintergrund: In dieser Anwendungsbeobachtung wird zum ersten Mal die Behandlung des Reizdarmsyndroms (RDS) mit einem homöopathisch-phytotherapeutischen Komplexpräparat beschrieben. Methodik: Ziel der 6-wöchigen Therapie mit dem Magen-Darm-Entoxin N® war die Reduzierung der RDS-Symptomatik sowie die Verbesserung der Lebensqualität. Zielkriterien waren die Veränderungen in der Irritable Bowel Syndrome - Severity Scoring System (IBS-SSS) und der Irritable Bowel Syndrome - Quality-of-Life Scale (IBS-QoL). Die Patient/innen (N = 41; Alter 44,0 ± 15,74 Jahre) wurden zu gleichen Teilen in einer Hausarztpraxis (N = 20) und einer Heilpraktikerpraxis (N = 21) rekrutiert. Ergebnisse: Der IBS-QoL-Score verringerte sich signifikant (prä: 35,9 ± 16,3; post: 20,1 ± 13,4; t = 8,504; p < 0,001). Die Effektstärke betrug 1,34 (Cohens d). Der IBS-SSS-Score verringerte sich ebenfalls signifikant (prä: 239,4 ± 83,4; post: 123,7 ± 80,9; t = 7,825; p < 0,001) mit einer Effektstärke von d = 1,24. Die Neben- und Wechselwirkungen waren minimal und signifikante Unterschiede zwischen beiden Praxen wurden nicht gefunden. Schlussfolgerungen: Magen-Darm-Entoxin N® ist eine sichere und sinnvolle Therapieoption bei der Behandlung des RDS. Allerdings sollten randomisierte kontrollierte Studien folgen, um die Spezifizität der Ergebnisse dieser Anwendungsbeobachtung zu stützen.

show abstract

Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating

Cited by 62 publications

References 8 publications

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota

Homöopathisch-phytotherapeutische Behandlung des Reizdarmsyndroms mit Magen-Darm-Entoxin N®: Eine Anwendungsbeobachtung

Contact Info

Product

Resources

About